- Home
- ORIC vs COLL Comparison
ORIC vs COLL Comparison
Compare ORIC & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- COLL
- Stock Information
- Founded
- ORIC 2014
- COLL 2002
- Country
- ORIC United States
- COLL United States
- Employees
- ORIC N/A
- COLL N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- ORIC Health Care
- COLL Health Care
- Exchange
- ORIC Nasdaq
- COLL Nasdaq
- Market Cap
- ORIC 974.1M
- COLL 958.8M
- IPO Year
- ORIC 2020
- COLL 2015
- Fundamental
- Price
- ORIC $11.07
- COLL $36.16
- Analyst Decision
- ORIC Strong Buy
- COLL Strong Buy
- Analyst Count
- ORIC 8
- COLL 4
- Target Price
- ORIC $16.57
- COLL $44.25
- AVG Volume (30 Days)
- ORIC 961.7K
- COLL 444.4K
- Earning Date
- ORIC 11-11-2025
- COLL 11-06-2025
- Dividend Yield
- ORIC N/A
- COLL N/A
- EPS Growth
- ORIC N/A
- COLL N/A
- EPS
- ORIC N/A
- COLL 1.06
- Revenue
- ORIC N/A
- COLL $707,007,000.00
- Revenue This Year
- ORIC N/A
- COLL $22.23
- Revenue Next Year
- ORIC N/A
- COLL $2.78
- P/E Ratio
- ORIC N/A
- COLL $34.01
- Revenue Growth
- ORIC N/A
- COLL 22.61
- 52 Week Low
- ORIC $3.90
- COLL $23.23
- 52 Week High
- ORIC $14.67
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- ORIC 58.52
- COLL 46.84
- Support Level
- ORIC $10.37
- COLL $34.71
- Resistance Level
- ORIC $11.16
- COLL $36.57
- Average True Range (ATR)
- ORIC 0.54
- COLL 1.27
- MACD
- ORIC 0.04
- COLL -0.58
- Stochastic Oscillator
- ORIC 82.14
- COLL 28.60
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.